AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 JUN 3 - (NewsRx.com & NewsRx.net) -- The protective role of fibulin-1 (Fbln-1) in breast cancer patients has been elucidated.
According to recent research from Italy, Fbln-1 is "an immunogenic breast cancer-related glycoprotein identified by a serological analysis of cDNA expression library (SEREX) strategy."
Dendritic cells from "two breast cancer patients elicited a CD4+-mediated T-cell response to Fbln-1 presentation," in a study conducted by S.M. Pupa and coauthors at the National Institute for Treatment and Research on Cancer in Milan.
"In both patients, an antibody response to Fbln-1 was also found," the collaborators said. "By contrast, a Fbln-1-seronegative patient and a weakly seropositive patient demonstrated no such T-cell response. Analysis of human breast cancers for Fbln-1 RNA and protein expression revealed the presence of Fbln-1C and -1D variants.
"Fbln-1 was detected in the cytoplasm and at the cell surface of different human breast carcinoma cell lines," published data indicated. "Immunohistochemical analysis of 528 archival primary breast carcinomas showed the expression of Fbln-1 in 35% of the cases.
"When the immunohistochemical findings were compared against pathobiological information associated with each specimen, an inverse relationship between Fbln-1 and ...
Source: HighBeam Research, Protective role of fibulin-1 elucidated.